If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
91
results.
Updated on
05/06/2025 [07:29:00]
Absstract of: AU2023312737A1
Provided herein are vaccine composition comprising a
Absstract of: CN120081916A
本发明公开了一种鼠伤寒沙门菌特异性抗原片段及其在检测鼠伤寒沙门菌抗体中的应用。所述鼠伤寒沙门菌特异性抗原片段的氨基酸序列如SEQ ID NO.1所示。本发明首次公开了以鼠伤寒沙门菌特异性抗原片段作为间接ELISA的包被抗原，建立了鼠伤寒沙门菌间接ELISA抗体检测方法，鼠伤寒沙门菌特异性抗原片段含有鼠伤寒沙门菌FliC蛋白的优势B细胞表位，能够特异性识别诱导产生的鼠伤寒沙门菌FliC蛋白抗体，在提高抗原抗体特异性结合方面有显著性的增效作用。本发明能够用于鼠伤寒沙门菌抗体的检测，为鼠伤寒沙门菌的流行病学调查以及沙门菌的防控提供了有力的技术支持。
Absstract of: US2025170230A1
The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
Absstract of: US2025169515A1
A continuous feed, shell egg pasteurization system and method uses sprayed heated water. The unpasteurized shell eggs are conveyed and rotated through a horizontal tunnel. An overlapping pattern of heated water is sprayed downward onto the rotating shells eggs. Verified testing shows that the shell eggs achieve a statistical 5 log reduction of Salmonella enteritidis that may have been present in the yolk in the respective unpasteurized shell egg, while at the same time are not overcooked and have little to no whitening of the albumen.
Absstract of: AU2023361317A1
The present invention relates to a modified live attenuated Gram-negative bacteria, wherein said bacteria has been modified in such a way that RNA molecules can be safely and efficiently delivered to target eukaryotic cells. As such, the present invention relates a to a bacterial delivery system and various uses and methods thereof.
Absstract of: US2023406892A1
The present invention relates to bacteriocins for control of Salmonella enterica (salmocins). The bacteriocins are derived from Salmonella. The salmocins can be expressed in plants and can be used in a method of preventing or reducing infection or contamination of an object with Salmonella.
Absstract of: US2025161423A1
The present invention relates to self-assembling protein nanoparticles encapsulating immunostimulatory nucleid acids. Furthermore, the invention relates to the use of such nanoparticles for vaccination.
Absstract of: AU2024256082A1
The present invention relates to the technical field of probiotics, in particular to a Lactiplantibacillus plantarum GOLDGUT-LP618 having a function of resisting Salmonella infection and application thereof. The Lactiplantibacillus plantarum GOLDGUT-LP618 provided by the present invention is preserved in China General Microbiological Culture Collection Center, with the preservation number of CGMCC No. 28399. The strain has high resistance to acid and bile salt and can adapt to the digestive tract environment. The strain can inhibit Salmonella infection, relieve diarrhea, inflammation and intestinal damage caused by Salmonella infection, and promote intestinal health. The strain can be used for preparing functional foods, dietary supplements or drugs that can resist Salmonella infection and improve diarrhea and inflammation caused by Salmonella infection, and has good application prospects.
Absstract of: WO2025102801A1
Provided are a method for preparing freezing shock-treated monocytes or macrophages loaded with attenuated Salmonella and the use thereof. The method comprises: loading engineering-modified attenuated Salmonella in monocytes or macrophages, and performed a freezing shock treatment on the monocytes or macrophages loaded with the strain by means of liquid nitrogen. The method for preparing the freezing shock-treated immune cells loaded with the strain is simple and easy to operate. The source problem of the monocytes or macrophages loaded with the engineering-modified attenuated Salmonella is solved, and the method has good application prospects. According to the strategy, by means of avoiding exposure and heterologous stimulation of bacteria, the biological safety of bacteria-based anti-tumor treatment is improved; and the anti-tumor immune response is promoted by means of the high titer of an intratumoral strain, so that a stronger anti-tumor efficacy is obtained.
Absstract of: US2025164483A1
Herein are presented methods for incorporating a novel bacteriophage, CAM-21, that exhibits lytic activity against pathogenic E. coli, into food, food packaging, films, and quantum dot-based biosensors. The bacteriophage contains no genes associated with toxins, virulence factors, antibiotic resistance, lysogeny, or allergens. Methods are provided for encapsulating the bacteriophage with proteins and/or carbohydrate materials to enhance stability. Various films in which the bacteriophage are incorporated, and which similarly exhibit suppression of pathogenic E. coli, are also provided. Additionally, when conjugated with N-doped graphene quantum dots, CAM-21 enables biosensor development for E. coli detection in food products through altered photoluminescence emission spectra, and methods for making and using such biosensors are provided.
Absstract of: AU2023382983A1
The present invention relates to a DNA construct including: a gene encoding a flagellin protein; and a gene encoding an immunoenhancer (adjuvant) protein. For effective cancer therapy by selectively killing only cancer cells, an attenuated Salmonella strain according to the present disclosure is designed to produce immunogenic substances in cancer tissue to induce a strong anti-cancer immune response, whereby tumor sizes in metastatic cancers as well as primary cancers can be significantly inhibited. Thus, the strain can be advantageously used in a prophylactic or therapeutic composition for improving survival rates.
Absstract of: WO2025100987A1
Cyclic dinucleotides, which are a type of signaling substance for cancer treatment, are secondary messengers of intracellular events initiated by GPCR activation and act as a stimulator of interferon genes (STING), and thus can have a significant effect on tumor suppression. Meanwhile, when cancer occurs in a subject, angiogenesis and cell growth proceed at a very high rate in the body, and thus an oxygen-deficient environment is created due to incomplete angiogenesis in cancer tissues, which may be very suitable for the proliferation of anaerobic bacteria such as Salmonella sp. strains or E. coli. Therefore, the present invention relates to a DNA construct into which is introduced a gene for an enzyme that synthesizes a signaling substance for cancer treatment, e.g., a cyclic dinucleotide, or to a strain transformed with a vector comprising the DNA construct. The DNA construct or the strain transformed with a vector comprising the DNA construct, according to the present invention, targets cancer in a subject and then secretes C-di-AMP or C-di-GMP synthase in the surrounding environment of the cancer, and thus can very effectively prevent or treat cancer and, at the same time, can diagnose cancer in real time.
Absstract of: AU2023312737A1
Provided herein are vaccine composition comprising a
Absstract of: WO2025092264A1
Provided in the present invention are Streptococcus salivarius subsp.thermophilus VB331 and the use thereof. The strain is deposited at the China General Microbiological Culture Collection Center, with the deposit number of CGMCC NO.28407. The Streptococcus salivarius subsp.thermophilus can effectively inhibit the colonization, propagation and growth of various digestive tract pathogenic bacteria, including Escherichia coli, Staphylococcus aureus, Salmonella, Enterococcus faecalis, Listeria monocytogenes and Shigella, and especially has a strong inhibitory effect on Clostridium perfringens. The strain is a natural strain, is very safe, and can provide a new source of probiotics for the development of antibacterial, bacteriostatic and other functional products against multiple harmful bacterial infections.
Absstract of: US2025147011A1
Disclosed is a covalently-linked multilayered three-dimensional matrix comprising capture molecules, linkers and spacers (referred to as a Molecular Net) for specific and sensitive analyte capture from a sample. Also disclosed herein is a Molecular Net comprising covalently-linked multilayered three-dimensional matrix comprising more than one type of capture molecule and more than one type of linker and may comprise one or more spacer for specific and sensitive capture of more than one type of analyte from a sample. A Molecular Net may comprise a pseudorandom nature. Use of various capture molecules, linkers and spacers in a Molecular Net may confer unique binding properties to a Molecular Net. Porosity, binding affinity, size exclusion abilities, filtration abilities, concentration abilities and signal amplification abilities of a Molecular Net may be varied and depend on the nature of components used in its fabrication. Uses of a Molecular Net may include analyte capture, analyte enrichment, analyte purification, analyte detection, analyte measurement and analyte delivery. Molecular Nets may be used in liquid phase or on solid phases such as nanomaterials, modified metal surfaces, nanospheres, microspheres, microtiter plates, slides, pipettes, cassettes, cartridges, discs, probes, lateral flow devices, microfluidics devices, microfluidics devices, optical fibers and others.
Absstract of: CN119932072A
本发明公开了一种减毒鼠伤寒沙门氏菌EN‑VNP菌株及其制备方法和应用，减毒鼠伤寒沙门氏菌EN‑VNP菌株的制备方法，包括如下步骤：在沙门氏菌VNP20009菌株基础上依次敲除或沉默鞭毛蛋白基因fliC、fljB、磷酸乙醇胺转移酶基因eptA、4‑氨基‑4‑脱氧‑L‑阿拉伯糖转移酶基因arnT、磷酸转移酶yeiU以及敲入或过表达磷酸转移酶基因lpxE之后形成的菌株，制得减毒鼠伤寒沙门氏菌EN‑VNP菌株。本发明的具有低毒和T细胞佐剂效果的减毒鼠伤寒沙门氏菌EN‑VNP及其制备的EN‑OMV抗原递送系统，使改善后的菌株不含有鞭毛蛋白且LPS分子结构发生改变，具有低毒和T细胞佐剂效果，且能够正常扩增培养。
Absstract of: WO2025090839A1
Described herein are compositions, methods, and kits for detecting diarrhea causing pathogens from patient, food, or environmental samples. One embodiment described herein is primer pairs and probes for multiplex polymerase chain reaction (PCR) based assays for the detection of gastrointestinal pathogens, such as Adenovirus, Astrovirus, Rotavirus, Norovirus, Sapovirus, Campylobacter species, Clostridium difficile, Enteroaggregative E. coli (EAEC), Enteropathogenic E. coli (EPEC), Enterotoxigenic E. coli (ETEC), Shiga-like toxin-producing E. coli (STEC), Shigella/Enteroinvasive E. coli (EIEC), E. coli O157, Listeria monocytogenes, Plesiomonas shigelloides, Salmonella species, Yersinia enterocolitica, Vibrio species, Cryptosporidium species, Cyclospora cayetanensis, Entamoeba histolytica, Giardia intestinalis, or Giardia lamblia. Other embodiments include methods and kits for detecting gastrointestinal pathogens.
Absstract of: US2025134980A1
The present disclosure relates to novel immunogenic monovalent and multivalent polysaccharide-protein conjugate vaccine compositions comprising a polysaccharide selected from Salmonella serovar strains S. typhi; S. paratyphi A; S. typhimurium and S. enteritidis and alternative improved methods of polysaccharide fermentation, polysaccharide purification, polysaccharide-protein conjugation and stable formulation. The present disclosure further relates to methods for inducing an immune response in subjects against Salmonella and non-typhi related diseases and/or for reducing or preventing Salmonella typhi and non-typhi related diseases in subjects using the compositions disclosed herein. The vaccine elicits bactericidal antibodies and is useful for prevention of gastroenteritis, enteric and typhoid fever.
Absstract of: EP4545628A1
The present application relates to a Limosilactobacillus fermentum MSJK0025 from breast milk for adjusting gut microbiota and an application thereof. The Limosilactobacillus fermentum MSJK0025 from breast milk is preserved in China General Microbiological Culture Collection Center, with a preservation number of CGMCC No.26426. The Limosilactobacillus fermentum from breast milk provided in the present application is a new strain separated from the healthy nursing woman, named as "Limosilactobacillus fermentum MSJK0025", having good antibiotics sensitivity, and its property can be stably inherited. It has good resistance to acid, bile salt, and artificial gastric juice and intestinal juice, and fast growth rate and good safety. At the same time, the strain has strong survival capability in the gut, and effectively inhibits pathogenic bacteria in the gut such as Escherichia coli, Staphylococcus aureus, Salmonella typhimurium, and Candida albicans, but does not inhibit the probiotic in the gut such as lactobacillus and bifidobacterium, so the strain has broad application prospect in adjusting the balance of gut microbiota.
Absstract of: AU2023312737A1
Provided herein are vaccine composition comprising a
Absstract of: WO2025081515A1
The present invention provides a tumor neoantigen vaccine system specifically marking a heterologous protein, and a use thereof. The vaccine system is composed of a heterologous protein mRNA vaccine and a recombinant oncolytic virus; the heterologous protein mRNA vaccine is used to induce an organism to generate heterologous protein-specific memory T cells, and the recombinant oncolytic virus is used to promote a tumor to express microorganism-derived tumor neoantigens. When pre-immunized memory T cells detect these marked specific neoantigens, the tumor expressing the neoantigens is quickly activated and killed, the release of tumor autoantigens is promoted, dendritic cells phagocytize antigens to further initiate an anti-tumor response, and a systemic anti-tumor immune effect is activated by means of antigenic epitope spreading.
Absstract of: US2025127889A1
The present disclosure relates to a composition for inducing migration of activated B cells to a germinal center, the composition including a substance that induces CD11b expression in B cells, a production method therefor, or use thereof. In one aspect, the present disclosure relates to immunostimulation and maintenance or improvement of mucosal flora using the substance that induces the CD11b expression in B cells.
Absstract of: WO2025081938A1
Provided is a method for preparing a biofloc culture medium by using organic wastes. The method comprises: adding a first auxiliary material to organic wastes, uniformly mixing same to obtain a mixture, and adjusting the water content of the mixture to 45-55%; inoculating an activated Bacillus subtilis seed culture, Bacillus licheniformis seed culture and Saccharomyces cerevisiae seed culture into the mixture according to a ratio, and performing fermentation with stirring and ventilation, so as to obtain a fermented product; adding a second auxiliary material to the fermented product, and uniformly mixing same to obtain the biofloc culture medium. In the finished biofloc product prepared by the method, the viable count of Bacillus subtilis is greater than or equal to 400 million cfu/g, the viable count of Bacillus licheniformis is greater than or equal to 200 million cfu/g, the viable count of Saccharomyces cerevisiae is greater than or equal to 1200 million cfu/g, the total number of bacterial colonies is greater than or equal to 8000 million cfu/g, and no salmonella is detected. The present application can solve the pollution problem of livestock and poultry manure and further achieves recycling utilization of livestock and poultry manure.
Absstract of: AU2023262222A1
The invention relates to a gelled reaction medium for the detection, identification, enumeration and/or isolation of at least one target microorganism in a sample that may contain same, comprising at least one binding partner specific to a component of a target microorganism or of a component derived from said microorganism, coupled to at least one nanoparticle to form at least one binding conjugate.
Nº publicación: CN119842745A 18/04/2025
Applicant:
扬州大学
Absstract of: CN119842745A
本发明公开了鼠伤寒沙门菌毒力基因Ict的鉴定及其减毒疫苗候选株的制备与应用。本发明选择强毒力鼠伤寒沙门菌SL1344株作为亲本株，将其中降解代谢衣康酸的关键毒力基因Ict进行敲除，构建鼠伤寒沙门菌SL1344减毒疫苗候选株。通过小鼠动物毒力实验、免疫保护力实验和安全性实验等证实该疫苗候选株SL1344‑ΔIct缺失株，不仅对动物的致病力显著降低，且提供了良好的免疫原性和免疫保护力。本发明实现对强毒力鼠伤寒沙门氏菌株的减毒，可广泛应用于沙门菌的防控，为研制沙门菌的减毒活疫苗及活载体疫苗奠定基础。
BOPI
Electronic site
